Lack of benefit from PD-1/PD-L1 inhibitors in pancreatic cancer is thought to arise from multiple reasons such as lack of immune cell infiltration, their dysfunction, low mutational burden, immunosuppressive tumor microenvironment (TME), and dense stroma limiting drug perfusion [7, 8]. Here, PDCD1 is linked to familial pancreatic carcinoma.